Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy

Tschautscher, Marcella; Jevremović, Dragan; Rajkumar, S. Vincent; Dispenzieri, Angela; Lacy, Martha Q.; Gertz, Morie A.; Buadi, Francis K.; Dingli, David; Hwa, Yi L.; Fonder, Amie; Hobbs, Miriam; Hayman, Suzanne R.; Zeldenrust, Steven R.; Lust, John A.; Russell, Stephen J.; Leung, Nelson; Kapoor, Prashant; Go, Ronald S.; Lin, Yi; Gonsalves, Wilson I.; Kourelis, Taxiarchis; Warsame, Rahma; Kyle, Robert A.; Kumar, Shaji

doi:10.1002/ajh.25481

Cited by 15 publications

(11 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Secondly, we do not provide details regarding the status of soft tissue plasmacytomas via imaging to correlate with our findings. Finally, while 64% of patients had detectable clonal plasma cells in the pre-transplant biopsy, in general the proportion of clonal PCs in these samples were found at low prevalence (median 0.55%), the relevance of which has been shown to correlate with improvement in clinical outcomes, especially if present at <5% 7 .…”

Section: Discussionmentioning

confidence: 88%

Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma

et al. 2020

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 88%

Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma

et al. 2020

Self Cite

View full text Add to dashboard Cite

“…MRD has offered important prognostic information for many hematologic malignancies, and tools to predict MRD have been invaluable. MM patients who achieve MRD have superior survival compared to those who do not [ 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 ]. The International Myeloma Working Group (IMWG) defines MRD as the persistence or re-emergence of malignant plasma cells, detectable at the level of one malignant cell in at least 1 × 10 5 normal cells.…”

Section: Current Molecular Diagnostic Workup For MM Including Fish Ng...mentioning

confidence: 99%

Review of Multiple Myeloma Genetics including Effects on Prognosis, Response to Treatment, and Diagnostic Workup

Wiedmeier-Nutor

Bergsagel

2022

Life

View full text Add to dashboard Cite

Multiple myeloma is a disorder of the monoclonal plasma cells and is the second most common hematologic malignancy. Despite improvements in survival with newer treatment regimens, multiple myeloma remains an incurable disease and most patients experience multiple relapses. Multiple myeloma disease initiation and progression are highly dependent on complex genetic aberrations. This review will summarize the current knowledge of these genetic aberrations, how they affect prognosis and the response to treatment, and review sensitive molecular techniques for multiple myeloma workup, with the ultimate goal of detecting myeloma progression early, allowing for timely treatment initiation.

show abstract

“…TTNT is not unique to CTCL for the measurement of DOCB. TTNT is a well-accepted endpoint in clinical trials of patients with multiple myeloma [ 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 ]. It also features in the published literature of clinical studies of patients with chronic lymphocytic leukaemia [ 29 , 30 , 31 , 32 , 33 , 34 ], follicular lymphoma [ 35 , 36 , 37 , 38 , 39 ], mantle cell lymphoma [ 40 ], amyloidosis [ 41 ], Waldenstrom macroglobulinaemia [ 42 , 43 ], autoimmune haemolytic anaemia [ 44 ], metastatic melanoma [ 45 ], and metastatic breast cancer [ 46 ].…”

Section: Use Of Ttnt In Other Diseasesmentioning

confidence: 99%

Time to Next Treatment as a Meaningful Endpoint for Trials of Primary Cutaneous Lymphoma

Campbell

Scarisbrick

Kim

et al. 2020

Cancers

View full text Add to dashboard Cite

Time to next treatment (TTNT) is an emerging endpoint in clinical studies of primary cutaneous T-cell lymphomas (CTCL), with utility as a surrogate marker for the “duration of clinical benefit”. TTNT provides a highly clinically meaningful endpoint that uniquely reflects not only the duration of treatment efficacy on disease and symptom control, but also incorporates the patient experience by accounting for patient compliance and tolerance to the studied therapy(s). Given the distinct challenges of pin-pointing the exact date of progression in patients with multi-compartmental CTCL, TTNT overcomes many of the shortcomings of conventional, disease-focused, clinical endpoints in primary CTCL research. Although widely accepted in clinical research for numerous other incurable malignancies, TTNT currently lacks a standardised definition. In this paper, we describe the value of TTNT as a clinical endpoint, review the applications of TTNT in primary CTCL research, and propose a standardised definition of TTNT to be applied in future clinical research of primary CTCL therapies.

show abstract

Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy

Abstract: Achievement of a complete response has been associated with improved outcomes in patients with multiple myeloma. Recently, increasing application of minimal residual disease (MRD) assessment has shown that MRD negativity is a powerful prognos-

Cited by 15 publications

References 21 publications

Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma

Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma

Review of Multiple Myeloma Genetics including Effects on Prognosis, Response to Treatment, and Diagnostic Workup

Time to Next Treatment as a Meaningful Endpoint for Trials of Primary Cutaneous Lymphoma

Contact Info

Product

Resources

About